JPS59195161A - Magnetic particle and its production - Google Patents

Magnetic particle and its production

Info

Publication number
JPS59195161A
JPS59195161A JP58069112A JP6911283A JPS59195161A JP S59195161 A JPS59195161 A JP S59195161A JP 58069112 A JP58069112 A JP 58069112A JP 6911283 A JP6911283 A JP 6911283A JP S59195161 A JPS59195161 A JP S59195161A
Authority
JP
Japan
Prior art keywords
particles
soln
gelatin
solution
metaphosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58069112A
Other languages
Japanese (ja)
Other versions
JPH0317103B2 (en
Inventor
Mikio Ikeda
池田 幹雄
Shiro Sakamoto
坂元 司郎
Kazumasa Suzuki
一正 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Priority to JP58069112A priority Critical patent/JPS59195161A/en
Publication of JPS59195161A publication Critical patent/JPS59195161A/en
Publication of JPH0317103B2 publication Critical patent/JPH0317103B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hard Magnetic Materials (AREA)

Abstract

PURPOSE:To obtain magnetic particles suitable for immobilizing of a living body component by adjusting a soln. mixture contg. gelatin, water soluble polysaccharide, metaphosphate and pulverous ferromagnetic material particles in a specific pH range then forming the insoluble particles within a specific grain size range by an aldehyde crosslinking agent. CONSTITUTION:Pulverous ferromagnetic material particles are dispersed in an aq. soln. contg. sodium metaphosphate and an anionic surface active agent. The dispersion is added to the mixed soln. obtd. by adding an aq. soln. of polysoccharide such as gum arabic removed of insoluble matter to an aq. soln. of gelatin adjusted with pH 9 and further mixing an aq. soln. of C2H5OH. The gelatin soln. dispersed therein with the magnetic particle is adjusted to 2.5-6pH with an aq. acetic acid and after the soln. is cooled to about 5 deg.C, a crosslinking agent such as glutaraldehyde or the like is added under stirring thereby obtaining hydrophilic and insoluble particles having 1-100mu grain size are obtd. Such particles are utilized for a solid carrier, etc. which permit easy operation such as washing and separation by taking advantage of the magnetic characteristic when a living component such as antigen, antibody or the like is going to be immobilized.

Description

【発明の詳細な説明】 不発明は、強磁性体微粒子を含み、抗原、抗体、酵素等
の各種蛋白類、糖蛋臼等の複合蛋白類及び糖類なとを固
定化しうる新規な粒子とその製造方法に関するものであ
る。
[Detailed Description of the Invention] The present invention relates to novel particles that contain ferromagnetic fine particles and are capable of immobilizing various proteins such as antigens, antibodies, and enzymes, complex proteins such as glycoproteins, and sugars. This relates to a manufacturing method.

内部に強磁性体微粒子を含む粒子は医学あるいは薬学の
分野で種々の応用が期待されている。その製造方法とし
ては、例えばK +’ W i d d e r  ら
による、マグネタイへ粒子を血清アルブミンで被層後乳
化と熱処理を繰シ返す方法があるが、この方法は操作が
複雑であり、かつ得らhた粒子の安定性にも問題があっ
た。そこで、現在では各種スチレンポリマーあるいはポ
リアクリルアミドなどの合成ラテックスを用いる方法が
主に研究されているが、この方法もやはシ操作が難しく
、質の揃った粒子を得にくいという問題点がめった。こ
の製法の難しさは、強磁体微粒子が極めて凝集しやすい
ことにあシ、このため、特に強磁性体微粒子の含有率の
筒い粒子を製造するととは至難であった。
Particles containing ferromagnetic particles inside are expected to have various applications in the medical and pharmaceutical fields. As a method for producing it, for example, there is a method by K+' Widder et al. in which particles are coated with serum albumin in a magnetite and then emulsification and heat treatment are repeated, but this method is complicated in operation; There was also a problem with the stability of the obtained particles. Therefore, currently research is mainly focused on methods using various styrene polymers or synthetic latexes such as polyacrylamide, but these methods also have the problem of being difficult to operate and difficult to obtain particles of uniform quality. The difficulty of this manufacturing method is that the ferromagnetic fine particles are extremely prone to agglomeration, and for this reason, it has been extremely difficult to manufacture cylindrical particles with a particularly high content of ferromagnetic fine particles.

本発明者らは、先に開発して特許出願したゼラチン粒子
の製造法(特開昭57−153658号など)がこの粒
子の製造法として極めて好適であり、この方法を用いれ
ば強磁性体微粒子の含有率の揃った均質の粒子を容易に
得られることを見出して、本発明を完成するに至った。
The present inventors believe that the method for producing gelatin particles that we previously developed and applied for a patent for (Japanese Unexamined Patent Publication No. 57-153658, etc.) is extremely suitable as a method for producing these particles. The present invention was completed based on the discovery that homogeneous particles with a uniform content of .

すなわち本発明は、(1)ゼラチン、水溶性多糖類、メ
タリン酸イオン及び強磁性体微粒子を含み、ゼラチンの
アミン基間がアルデヒドによって架橋さi、粒径が1〜
100μの球形であって親水性かつ不溶性の粒子と、(
2)ゼラチン、水溶性多糖類、メタリン酸塩及び強磁性
体微粒子を含有する混合溶液に酸を加えてpH2,5〜
6.0に調整し、その後アルデヒド系架橋剤を作用せし
めて溶液中に形成された球形粒子を不溶化することを特
徴とする粒子の製造法に関するものである。
That is, the present invention includes (1) gelatin, a water-soluble polysaccharide, metaphosphate ions, and ferromagnetic fine particles, the amine groups of the gelatin are crosslinked with aldehyde, and the particle size is 1 to 1.
100μ spherical, hydrophilic and insoluble particles, (
2) Add acid to a mixed solution containing gelatin, water-soluble polysaccharide, metaphosphate and ferromagnetic particles to pH 2.5~
The present invention relates to a method for producing particles, characterized in that the spherical particles formed in the solution are insolubilized by adjusting the particle diameter to 6.0 and then applying an aldehyde-based crosslinking agent to insolubilize the spherical particles formed in the solution.

ゼラチンは誘導蛋白質の一種であってコラーゲンよシ得
られたものである。ゼラチンのなかでは酸性ゼラチンが
特に好ましい。
Gelatin is a type of derived protein obtained from collagen. Among gelatins, acidic gelatin is particularly preferred.

水溶性多糖類は増粘剤または糊料として使用しうるもの
であシ、多糖類の誘導体および塩も含まれる。例として
は、アラビアゴム、カルボキシメチルセルロース、アル
ギン酸ナトリウム、寒天、カラグーナンなどを挙げるこ
とができるが、特にアラビアゴムが好適である。
Water-soluble polysaccharides can be used as thickeners or thickeners, and also include derivatives and salts of polysaccharides. Examples include gum arabic, carboxymethyl cellulose, sodium alginate, agar, carrageenan, etc., with gum arabic being particularly preferred.

メタリン酸イオンはメタリン酸塩の一部の陽イオンが離
脱して形成される陰イオンであシ、その荷電数は粒子が
形成さハるpH,原料に用いたメタリン酸塩の種類など
に応じて定まる。メタリン酸塩はたとえば三ツタリン酸
ナトリウム、ヘキサメタリン隘ナトリウムの如きもので
ある。
Metaphosphate ions are anions formed when some cations of metaphosphate are separated, and the number of charges depends on the pH at which particles are formed, the type of metaphosphate used as a raw material, etc. It is determined. Metaphosphates include, for example, sodium mitsutaphosphate and sodium hexametaphosphate.

強磁性体微粒子は、鉄、コバルト、ニッケル等とマグネ
タイト等のフェライトなどの微粒子である。強磁性体微
粒子の太きさけ、要はとの微粒子が溶液内を攪拌等によ
ってほぼ均一に浮遊でき名はよく、通常は50〜500
八〇程度の粒径でよい。
The ferromagnetic fine particles are fine particles of iron, cobalt, nickel, etc., and ferrite such as magnetite. It is well known that ferromagnetic fine particles with a diameter of approximately 50 to 500 mm are suspended almost uniformly in a solution by stirring, etc.
A particle size of about 80 is sufficient.

強磁性体微粒子は予め液中に分散させてから添加するの
がよく、分散状態を維持するために陰イオン系及び非イ
オン系の界面活性剤など′ff:適宜使用する。このよ
うな分散状態のもののal・とじてフェリコロイド(ク
イホーエ業■製)などがある。
The ferromagnetic fine particles are preferably added after being dispersed in the liquid in advance, and anionic and nonionic surfactants and the like are used as appropriate to maintain the dispersion state. In such a dispersed state, there are Al and Tojitoferricolloid (manufactured by Kuiho Industries).

不祈明の粒子においては、ゼラチンのアミン基間かアル
デヒドによって架橋さ1ておシ、水溶性多糖類とメタリ
ン酸イオンはゼラチンと静電的((結合している。そし
て、メタリン酸イオンは粒子の内部にも含まわているが
、特に表面を取シ巻いて電気二重層を形成しているもの
と思われる。また、強磁性体微粒子はこのような粒子全
体にわたって分布している。
In the particles, water-soluble polysaccharides and metaphosphate ions are electrostatically bonded to gelatin, and the metaphosphate ions are cross-linked by aldehydes between the amine groups of gelatin. Although it is contained inside the particles, it is thought that it wraps around the surface in particular to form an electric double layer.Furthermore, the ferromagnetic fine particles are distributed throughout such particles.

このような粒子の大部分は水であシ、組成としてはゼラ
チンが2〜10%程度、水溶性多糖類が1〜5%程度、
メタリン酸イオンが0.01〜5%程度、強磁性体微粒
子が0.000001〜10係程度、そして水分が60
〜90%程度である。粒子は着色されている場合には色
素を含み、また、製法に応じて界面活性剤、親水性有機
溶媒などが混入している場合もある。
Most of these particles are made of water, with a composition of about 2 to 10% gelatin, about 1 to 5% water-soluble polysaccharide,
Metaphosphate ions are about 0.01 to 5%, ferromagnetic fine particles are about 0.000001 to 10%, and water is about 60%.
It is about 90%. When the particles are colored, they contain a pigment, and depending on the manufacturing method, they may also contain surfactants, hydrophilic organic solvents, and the like.

本発明の粒子の物性を次に示す。The physical properties of the particles of the present invention are shown below.

(11電気泳動度 25℃におけるpH7,2の0.15Mリン酸塩緩衝生
理食塩水(以下、PBS  と略記する。)中ての本発
明の粒子の電気泳動度は0.7〜1.5μm/sec 
/V/のにある。
(11 Electrophoretic mobility The electrophoretic mobility of the particles of the present invention in 0.15M phosphate buffered saline (hereinafter abbreviated as PBS) at pH 7.2 at 25°C is 0.7 to 1.5 μm. /sec
It's in /V/.

(2)外形 直径1〜100μの球形である。(2) External shape It is spherical with a diameter of 1 to 100μ.

なお、3000倍の走査型電子顕微鏡写真を脂1図に示
す。
A scanning electron micrograph at 3000x magnification is shown in Figure 1.

(3)電子顕微鏡写真 10000倍の透過型電子顕微鏡写真を第2図に示す。(3) Electron micrograph A 10,000x transmission electron micrograph is shown in Figure 2.

図に示されるように強磁性体微粒子は粒子全体にほぼ均
一に分布している。
As shown in the figure, the ferromagnetic fine particles are distributed almost uniformly throughout the particles.

(4)色 特に着色しなければ白〜淡黄色不透明である=(5)水
に対する態度 親水性 (6)活性蛋白の固定化 本発明の粒子は抗原あるいは抗体をヒツジ赤血球に感作
する公知の方法によってとわらを感作することができ、
酵素、リンホカイン等の他の活性蛋白を固定化すること
ができる。このような感作方法の例トしてはlンニン酸
、ホルマリン、グルメルアルデヒド、ピルビックアルデ
ヒド、ビス−ジアゾ化ベンジジン、トルエン−2,4−
ジイソシアナートなどを用いる方法を挙けることができ
る。
(4) Color: white to pale yellow and opaque unless specifically colored = (5) Attitude toward water: Hydrophilic (6) Immobilization of active protein The particles of the present invention are known to sensitize sheep red blood cells to antigens or antibodies. The straw can be sensitized by the method,
Other active proteins such as enzymes, lymphokines, etc. can be immobilized. Examples of such sensitization methods include phosphoric acid, formalin, glumeraldehyde, pyruvic aldehyde, bis-diazotized benzidine, toluene-2,4-
A method using diisocyanate and the like can be mentioned.

また、不発明の粒子はアミノ基、カルボキシル基、水酸
基などを活用して酵素を固定化する公知の方法によって
酵素、あるいは抗原、抗体など各種の活性蛋白を固定化
することもできる。このような固定化法の例として、ソ
アゾカツプリング法、酸アジド化法などを挙げることが
できる。
Furthermore, enzymes or various active proteins such as antigens and antibodies can be immobilized on the uninvented particles by a known method of immobilizing enzymes using amino groups, carboxyl groups, hydroxyl groups, etc. Examples of such immobilization methods include the soazo coupling method and the acid azidation method.

(7)糖蛋白等の複合蛋白類及び糖類の固定化複合蛋白
類は(6)の活性蛋白の固定化と同じ方法によって固定
できる。又、糖類は例えは、過ヨウ素酸等の酸化剤を用
いて固定することができる。
(7) Immobilization of complex proteins such as glycoproteins and sugars Complex proteins can be immobilized by the same method as in (6) for immobilization of active proteins. Furthermore, sugars can be fixed using, for example, an oxidizing agent such as periodic acid.

このような本発明の粒子は、前述のゼラチン、水溶性多
糖類、メタリン酸塩及び強磁性体微粒子を含む混合溶液
を攪拌しつつそこに酸を加えてpH2,5〜6.0に調
整し、その後アルデヒド系架橋剤を作用せしめて不溶化
することによって製造することができる。
Such particles of the present invention can be obtained by adding an acid to a mixed solution containing gelatin, a water-soluble polysaccharide, a metaphosphate, and ferromagnetic particles while stirring to adjust the pH to 2.5 to 6.0. , and then insolubilized by the action of an aldehyde crosslinking agent.

この場合、pH調整前の溶液におけるとnら各物質の濃
度としては、ゼラチン0.01〜5%程度、好ましくは
0.05〜1.0程度、水溶性多糖類0.01〜5係程
度、好ましくは0.05〜1.0多相度、そして強磁性
体微粒子0.000001〜15チ程度である。
In this case, the concentration of each substance in the solution before pH adjustment is about 0.01 to 5% for gelatin, preferably about 0.05 to 1.0%, and about 0.01 to 5% for water-soluble polysaccharide. , preferably 0.05 to 1.0 multiphase degree, and ferromagnetic fine particles of about 0.000001 to 15 inches.

メタリン酸塩はゼラチン乾燥重量の1〜3%程度を含有
させるようにするのがよい。各物質はとわらの濃度範囲
において、所望の粒子の粒径および物性に応じて適宜定
めjはよい。
The metaphosphate is preferably contained in an amount of about 1 to 3% of the dry weight of gelatin. The concentration of each substance may be appropriately determined within the range of concentration according to the particle size and physical properties of the desired particles.

pH調整前の溶液にはそのほかのものとして、親水性有
機溶媒、界面活性剤、着色剤などを適宜加える。
In addition, a hydrophilic organic solvent, a surfactant, a coloring agent, etc. are appropriately added to the solution before pH adjustment.

親水性有機溶剤は生成する粒子の物性、特に分散性およ
び硬さなどを改善することができる。親水性有機溶媒の
例としては、低級アルコール、たトエハメチルアルコー
ル、エチルアルコール、フロビルアルコール等、および
アセトンなどを用いることができ、濃度は4〜25容量
係程度が好適である。
Hydrophilic organic solvents can improve the physical properties of the particles produced, particularly their dispersibility and hardness. Examples of the hydrophilic organic solvent that can be used include lower alcohols, ethyl alcohol, ethyl alcohol, flobyl alcohol, and acetone, and the concentration is preferably about 4 to 25 volumes.

界面活性剤は生成した粒子の凝集を防止して分散を維持
するためであシ、陰イオン系または非イオン系のものが
よい。
The surfactant is used to prevent agglomeration of the generated particles and maintain dispersion, and is preferably an anionic or nonionic surfactant.

陰イオン系界面活性剤の例としては、アルキルスルホコ
ハク酸、アルキルスルホマレイン酸、アルキル硫酸エス
テル、ポリオキシエチレンアルキルエーテル硫酸エステ
ルなど、そして非イオン系界面活性剤の例としては、ポ
リオキシエチレン脂肪駈エステル、ポリオキシエチレン
アルキルエーテル、ポリオキシエチレンアルキルフェニ
ルエーテル 、101JエチレングリコールJJit 
肪にエステル々とを挙げることができる。pH調整前の
溶液における濃度としては、陰イオン系界面活性剤の場
合は0.001〜0.O1%1%程非イオン系界面活性
剤の場合は0.01〜0.1多相度で凝集防止効果が得
られる。溶液を冷却すればもつと低い濃度で凝集を防止
することができる。
Examples of anionic surfactants include alkyl sulfosuccinic acids, alkyl sulfomaleic acids, alkyl sulfates, and polyoxyethylene alkyl ether sulfates, and examples of nonionic surfactants include polyoxyethylene fatty acids. Ester, polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, 101J ethylene glycol JJit
Fats include esters. In the case of anionic surfactants, the concentration in the solution before pH adjustment is 0.001 to 0. In the case of a nonionic surfactant of about 1% O, an aggregation prevention effect can be obtained at a polyphasic degree of 0.01 to 0.1. By cooling the solution, aggregation can be prevented at lower concentrations.

粒子を着色する場合には、殖色剤を粒子形成前に溶液に
加えて訃くのかよい。着色を必裂とする2゛1:とじて
は、本発明品を間接受身凝集反応の担体として用いる場
合を挙けることができる。すなわち、不発明品は通常は
白〜淡黄色不透明であるところから、こわを滋色するこ
とによって凝集像の判定を容易にすることかできる。鬼
色剤としてtr:x、たとえば食用赤色3号、ローダミ
ン、ローズベンガル、ポンソー3R,ボルドーS1フク
シン、エオシン、およびニュートラルレッドなどの赤色
色素、あるいはクリスタルバイオレット、トルイジンブ
ルー、ダイレクトブルーおよびメチレンブルーなどの青
色色素等を用いうる。しかしながら、リアクティブ・レ
ッド、リアクティブ・ブルーなどの反応性染料で着色す
九ば色落ちしないことがら、反応性染料が特に好適であ
る。着色剤を添加する場合には、通常は0.005〜0
.5%程度であるが、反応性染料を用いればゼラチン乾
燥重量の1〜555程度で足シる。
If the particles are to be colored, a color promoter may be added to the solution before forming the particles. 2.1: An example of the case where the product of the present invention is used as a carrier for an indirect passive aggregation reaction. That is, since non-inventive products are usually white to pale yellow and opaque, it is possible to make the determination of the agglomerated image easier by coloring the stiffness. As a dark coloring agent, tr: A dye or the like can be used. However, reactive dyes such as reactive red and reactive blue are particularly suitable because the color does not fade when colored with reactive dyes. When adding a colorant, it is usually 0.005 to 0.
.. The amount is about 5%, but if a reactive dye is used, it will be reduced to about 1 to 555% of the dry weight of gelatin.

このような溶液を調製する過程は問うところではなく、
例えば強磁性体微粒子を除く各々を泥水に溶踊−してか
ら混合してもよく、各々を一緒に溶解してもよい。しか
しながら、各物質の溶解を容易にするために親水性有様
溶媒はあとから加えるのかよく、捷だ水溶性多糖類には
不溶成分も少量含まれていることが多いところから、別
途に溶解して給かするのかよい。−万、ゼラチンは等電
点以]のpHでは水溶性多糖類と反応して白濁を生ずる
ので散性ゼラチッを用いる払合にはアルカリを加えて溶
液のpHを少なくともその付近にまで高めておくのがよ
い。しかし表から、この白濁は生じた後でもアルカリを
添加することによって消すことができる。いずれにせよ
、溶液は酸の添加を面始する捷えには強磁性体微粒子以
外には懸濁物のない状態にしておかなければならない。
The process of preparing such a solution is not in question;
For example, each of the components except the ferromagnetic fine particles may be dissolved in muddy water and then mixed, or each component may be dissolved together. However, in order to facilitate the dissolution of each substance, hydrophilic solvents are often added afterwards; however, since fresh water-soluble polysaccharides often contain small amounts of insoluble components, they must be dissolved separately. Should I give it to you? Gelatin reacts with water-soluble polysaccharides at a pH above its isoelectric point, producing cloudiness, so when using powdered gelatin, add alkali to raise the pH of the solution to at least around that point. It is better. However, the table shows that even after this cloudiness occurs, it can be eliminated by adding alkali. In any case, the solution must be free of suspended matter other than the ferromagnetic particles before addition of the acid.

強磁性体微粒子はこのような溶液を調製する任意の段階
で所定邦を添加し、懸濁させればよい。
The ferromagnetic fine particles may be suspended by adding a predetermined amount at any stage of preparing such a solution.

溶液の温度はゼラチンのケゝル化温WJJ上でなければ
ならない。このグル化温度はゼラチンの濃度切によって
異なるが通例25〜30℃程度である。
The temperature of the solution must be above the gelatin temperature WJJ. This gluing temperature varies depending on the concentration of gelatin, but is usually about 25 to 30°C.

良好な粒子形成の観点から特に35〜50℃程度がよい
、 次に、この溶液を攪拌しながら酸を加えてpH2,5〜
6.0に調整する。この工程は粒子を生成させるところ
である。均一な粒子を形成させるために、35〜50℃
に加温をわ[け、適度に攪拌し々から酸を滴下していく
のがよい。pH2,5〜6,0の範囲における至適のp
)Iは原料溶液の組成および目的とする粒径によって人
々るので予め実験を行なって定めるのがよい。たとえば
得らilだ粒子を抗原感作用担体に用いる場合には2〜
10μ程ハタの粒径にするのかよく、そのぢL合至述の
pH(、、:4.0〜5.5 (D gl・囲にある。
From the viewpoint of good particle formation, the temperature is particularly good at 35-50°C.Next, add acid to this solution while stirring to adjust the pH to 2.5-50°C.
Adjust to 6.0. This step is where particles are generated. 35-50℃ to form uniform particles
It is best to heat the mixture and add the acid dropwise while stirring moderately. Optimal p in the pH range of 2.5 to 6.0
) Since I varies depending on the composition of the raw material solution and the intended particle size, it is best to determine it by conducting experiments in advance. For example, when using the obtained IL particles as an antigen-sensitizing carrier,
The particle size should be about 10 μm, and the pH range is between 4.0 and 5.5 (Dgl).

このpHg、、(1整に使用する酸は4−−に限定さi
するものではなく無楼′・酸でも有声酸でもよいか、な
るべくおだやかなものがよく、たとえば酢酸などが好適
である。
This pHg, (the acid used for 1 adjustment is limited to 4--
The acid may be a non-rotating acid or a voiced acid, and preferably one that is as mild as possible, such as acetic acid.

本工程で生成し/こ粒子に」、系の温度ンゼラチンのグ
ル化温度以下に下げても消失しないので母液との平衡関
係はない。
The particles produced in this step do not disappear even if the temperature of the system is lowered below the gelatin gluing temperature, so there is no equilibrium relationship with the mother liquor.

酸の添加後は生成した粒子の凝集を防止するために速か
に粒子分散液を冷却するのがよい。そして、液温か10
℃以下になったところでアルデヒド系架橋剤を添加して
粒子ケ不溶化する。この架橋剤の添加量はゼラチン乾燥
重量の0.1〜200チ程度であシ、添加後は一侠程度
放置して架橋反応を充分に行なわせる。架橋剤の例とし
て(ri、グルタルアルデヒド、ホルムアルデヒド、グ
リオキザール、クロトンアルデヒド、アクロレイン、ア
セトアルデヒドなどを挙げることができるが、特にグル
タルアルデヒドが好適である。
After adding the acid, it is preferable to quickly cool the particle dispersion to prevent the formed particles from agglomerating. And the liquid temperature is 10
When the temperature drops below 0.degree. C., an aldehyde crosslinking agent is added to insolubilize the particles. The amount of this crosslinking agent added is about 0.1 to 200 g of the dry weight of gelatin, and after addition, the mixture is left to stand for about a minute to allow the crosslinking reaction to occur sufficiently. Examples of the crosslinking agent include (ri), glutaraldehyde, formaldehyde, glyoxal, crotonaldehyde, acrolein, and acetaldehyde, with glutaraldehyde being particularly preferred.

アルデヒド系架橋剤で処y1.後は粒子を遠心分離ある
いは磁力を利用する等して回収し、8会により洗浄する
。洗浄液は粒子分散のために用いた界面活性剤と同じも
のを同濃度で含む水で2〜3回行なえばよい3、 このように(〜てイuらス1.た粒子を柱々の用途に供
ずrlばよいが、架橋が不充分な場合には塩類溶液中で
膨潤することがある。そこで、このような用途に用いる
場合にはアルデヒド系架橋剤で処理して膨潤を防止する
のがよい。例えは、抗原全感作ツーる場合に1リン酸緩
飽液中で行なうの一イム赤血球?固定化する条件でネル
マリン処理する。この処理によって膨潤を防止するとと
もにホルマリンの殺菌効果によって長期間の保存に1え
る粒子が得らする。
Treatment with aldehyde crosslinking agent y1. Afterwards, the particles are collected by centrifugation or by using magnetic force, and washed by 8 washes. The cleaning solution can be washed two or three times with water containing the same surfactant at the same concentration as the surfactant used for particle dispersion. However, if crosslinking is insufficient, it may swell in a salt solution. Therefore, when used for such purposes, it is recommended to treat it with an aldehyde-based crosslinking agent to prevent swelling. For example, when total antigen sensitization is required, nermarin treatment is performed under the conditions of fixation of red blood cells in a mildly saturated monophosphate solution.This treatment prevents swelling and uses the bactericidal effect of formalin. Particles that can be stored for a long period of time are obtained.

不発甲iの粒子は、強磁性体微粒子か粒子中に均一に分
散しておシ、磁性をオ[1用しで洗浄あるいはIF81
収を?9易に行なうことかできる。壕プ辷、化学的、物
理的に均質かつ安定であって抗原活性がないところから
1Xij接受身凝莱反応の担体とり、−(好適であシ、
その場合凝集反応時間が約半分に短縮されるという利点
がある。不発明の粒子は蛋白質、複合蛋白質あるいは糖
類などを固定化する担体として好適であシ、磁性を利用
することによって種々の新たな用途への活用を期待でき
る。そして、このような粒子を前記の範囲において任意
の粒径及び強磁性体数粒子の含有率で容易かつ安価に大
片生産することができる。
The unexploded particles should be uniformly dispersed in ferromagnetic fine particles or washed with IF81 to remove the magnetism.
Revenue? 9 It is easy to do. From the point where the trench is chemically and physically homogeneous and stable and has no antigenic activity, the carrier for the passive coagulation reaction is taken, - (preferably,
In this case, there is an advantage that the aggregation reaction time is shortened by about half. The particles of the invention are suitable as carriers for immobilizing proteins, complex proteins, sugars, etc., and by utilizing their magnetism, they can be expected to be used in various new applications. Such particles can be easily and inexpensively produced in large pieces with any particle size and content of several ferromagnetic particles within the above range.

以下、実施例を示す。なお、不明a魯において係は特に
@e載がない限り重量係を表わしている。
Examples are shown below. In addition, in Unknown a Lu, the person in charge represents the person in charge of weight unless there is a special @e listing.

実施例 等電点がpH9である酸性ゼラチン41を40℃の温水
に100−に彦るように溶解し、10%の水酸化ナトリ
ウム溶液を用いてpH9に調整した。アラビアゴム4t
を100艷になるように水に溶解し、不溶物を炉別した
後40℃に加温した。
Example Acidic gelatin 41 having an isoelectric point of pH 9 was dissolved in warm water at 40° C. to a pH of 100° C., and the pH was adjusted to 9 using a 10% sodium hydroxide solution. gum arabic 4t
was dissolved in water to a volume of 100 ml, and after removing insoluble matter in a furnace, it was heated to 40°C.

このようにして得られたゼラチン溶液25m1とアラビ
アゴム溶液25−を混合し、この混合液をあらかじめ4
0℃に加温した30容i%のエチルアルコール溶液15
0−に注ぎ入れ、よく攪拌した。これに10係へキサメ
タリン酸ナトリウム溶液o、sy、to%アルキルスル
ホマレイン酸(商品名デモールEp、花王石鹸■製)溶
液1−1及ヒ平均粒径150A”のフェリコロイドW−
35(商品名、クイホーエ業@製) 60μt  (F
e  5.2■含有)又は300 μt(Fe  30
.4−++V含有)を加えてよく攪拌した。
Mix 25ml of the gelatin solution obtained in this way and 25ml of gum arabic solution, and add 4ml of this mixed solution in advance.
30 volume i% ethyl alcohol solution heated to 0°C 15
0- and stirred well. To this, solution 1-1 of sodium hexametaphosphate solution o, sy, to% alkyl sulfomaleic acid (trade name Demol Ep, manufactured by Kao Soap ■) and ferricolloid W- with an average particle size of 150A'' were added.
35 (product name, manufactured by Kuihoe Gyo@) 60μt (F
e 5.2■) or 300 μt (Fe 30
.. 4-++V-containing) was added and stirred well.

次いで、40℃に保ちながら10容−3M%の酢酸溶液
を滴下して第1表に記載するpHK調整し、粒子を生成
させた。
Next, while maintaining the temperature at 40° C., a 10 volume-3M% acetic acid solution was added dropwise to adjust the pH as shown in Table 1, thereby producing particles.

このpH調整によって得られた粒子分散液を氷冷して5
℃にしてからゲルタールアルデヒド0.651を加え、
よく攪拌後この温度で一夜静置した。
The particle dispersion obtained by this pH adjustment was cooled on ice and
℃, add 0.651 gel taraldehyde,
After stirring thoroughly, the mixture was allowed to stand overnight at this temperature.

それからこの粒子分散液を2000 rpmで1o分間
遠心分離して粒子をペレットとして回収した。
The particle dispersion was then centrifuged at 2000 rpm for 10 minutes to collect particles as pellets.

この粒子を0.005%デモールEp溶液に懸濁して遠
心分離する洗浄操作を3回繰返してから、4容量チホル
マリン溶液に分散し、5℃で1週間放置した。
A washing operation in which the particles were suspended in a 0.005% Demol Ep solution and centrifuged was repeated three times, then dispersed in 4 volumes of thiformin solution and left at 5° C. for one week.

得られた結果を第1表に示す。The results obtained are shown in Table 1.

こうして裟られた粒子を磁場を変えて沈降速度を求めそ
の結果を第2表に示す。尚、Qlj定(−i磁石上に血
沈管′fI:置き、その中に第2衣に示すいずれかの粒
子を5 v / v  %になるようにpf(7,2の
0゜15M1.lン酸緩衝生理食塩液中に均一に懸濁し
て投入して粒子面が、2.5の、5.0 cm及びIQ
o+を沈降するのに要する各時間を測定して行なった。
The sedimentation velocity of the thus-travelled particles was determined by changing the magnetic field, and the results are shown in Table 2. In addition, place the blood sedimentation tube 'fI: on a Qlj constant (-i magnet, and add any of the particles shown in the second column to the pf (0°15M1.l of 7,2) so that the concentration is 5 v/v%. The particle surface was uniformly suspended in acid-buffered saline and the particles had a particle size of 2.5 cm, 5.0 cm, and IQ.
Each time required for the o+ to settle was measured.

第    2    表 なお、液相置換法による真北ル値は、Fe、、0..0
゜2係含有粒子の場合には1.30〜1.40ぞして、
Fe、、Os 1.2 %含有粒子の場合には1.50
〜1.80でをンシ、Fe、、0.、を含まない粒子の
場合には1.01〜125であった。
Table 2 Note that the true north value determined by the liquid phase displacement method is Fe, 0. .. 0
In the case of particles containing ゜2 coefficient, it is 1.30 to 1.40,
1.50 for particles containing 1.2% Fe, Os
~1.80, Fe, 0. , in the case of particles not containing , it was 1.01 to 125.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は不発明の粒子の走査型電子b0微鏡写真であシ
、第2図は透過2Ti!!電子顕微鏡写真である。 判−註  出 願 人  富士レビオ株式会社代理人 
弁理士 田中政浩 第 1 図 手 続  補 正 店(自発) 昭和58年9月 G 口 1事件の表示 昭和58年特許願第69112号 2発明の名称 磁性粒子及びその製造法 3補正をする者 事件との関係  特許出願人 名称 富士レビオ株式会社 4代理人 居所 〒104東京都中央区京橋二丁目1番:3刊6補
正の内容 (1)明細書第4頁第6行目から第8行目「強硅性体微
粒子(d フェライトなどの微粒子で之る。」を以下の
通りに補正する。 U強磁性体とは磁気ヒステリシスを示す物少をいう。具
体的には鉄、コバルト、二、ケル又はこれらの合金等の
金属磁性体、フェライト(例えばマグネタイト)等の酸
化金属磁慴体が例としてあげられる。」 5頁16行 「07〜1.5J   r、−o7〜−1
5」5頁19行 「μ」     「μm」16頁表 
 「(μ)」「(μm)J
FIG. 1 is a scanning electron b0 micrograph of the uninvented particle, and FIG. 2 is a transmission 2Ti! ! This is an electron micrograph. Judgment - Notes Applicant Fujirebio Co., Ltd. Agent
Patent Attorney Masahiro Tanaka No. 1 Illustration Proceeding Amendment Office (Voluntary) September 1981 G Case 1 Display of Case 1989 Patent Application No. 69112 2 Name of Invention Magnetic Particles and Process for Producing the Same 3 Case of Person Who Amends Relationship with Patent applicant name Fujirebio Co., Ltd. 4 agent residence Address: 2-1 Kyobashi, Chuo-ku, Tokyo 104: 3rd edition Contents of 6th amendment (1) Specification, page 4, lines 6 to 8 "Ferromagnetic particles (fine particles such as ferrite, etc.)" is corrected as follows.U Ferromagnetic material refers to a substance that exhibits magnetic hysteresis.Specifically, iron, cobalt, ferrite, etc. Examples include metal magnetic materials such as Kel or their alloys, and oxidized metal magnetic materials such as ferrite (e.g. magnetite).'' Page 5, line 16 ``07~1.5J r, -o7~-1
5” page 5 line 19 “μ” “μm” page 16 table
"(μ)""(μm)J

Claims (1)

【特許請求の範囲】 1 ゼラチン、水溶性多糖類、メタリン酸イオン及び強
磁性体微粒子を含み、ゼラチンのアミン基間がアルデヒ
ドによって架橋さね、粒径が1〜100μの球形であっ
て親水性かつ不溶性の粒子 2 ゼラチン、水溶性多糖類、メタリン酸塩及び強磁性
体微粒子を含有する混合溶液に酸を加えてpH2,5〜
6]0に調整し、その後アルデヒド系架橋剤を作用せし
めて溶液中に形成された球形粒子を不溶化することを特
徴とする粒子の製造法
[Claims] 1. A gelatin containing gelatin, a water-soluble polysaccharide, a metaphosphate ion, and ferromagnetic fine particles, in which the amine groups of the gelatin are cross-linked with aldehyde, and the particles are spherical and hydrophilic with a particle size of 1 to 100μ. and insoluble particles 2 Add acid to a mixed solution containing gelatin, water-soluble polysaccharide, metaphosphate, and ferromagnetic fine particles to pH 2.5 ~
6] A method for producing particles, which comprises adjusting the particle size to 0 and then applying an aldehyde crosslinking agent to insolubilize the spherical particles formed in the solution.
JP58069112A 1983-04-21 1983-04-21 Magnetic particle and its production Granted JPS59195161A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58069112A JPS59195161A (en) 1983-04-21 1983-04-21 Magnetic particle and its production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58069112A JPS59195161A (en) 1983-04-21 1983-04-21 Magnetic particle and its production

Publications (2)

Publication Number Publication Date
JPS59195161A true JPS59195161A (en) 1984-11-06
JPH0317103B2 JPH0317103B2 (en) 1991-03-07

Family

ID=13393221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58069112A Granted JPS59195161A (en) 1983-04-21 1983-04-21 Magnetic particle and its production

Country Status (1)

Country Link
JP (1) JPS59195161A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61181967A (en) * 1984-11-01 1986-08-14 バイヤー、コーパレイシャン Magnetic reactive particle and manufacture thereof
JPS61289053A (en) * 1985-06-14 1986-12-19 Osaka Yuki Kagaku Kogyo Kk Production of 1,3-dichloroacetone
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS6390766A (en) * 1986-10-03 1988-04-21 Tdk Corp Suspension of fine magnetic particles antigen-antibody with immobilized and method for measuring concentration of antigen or antibody by using said suspension
WO1990009590A1 (en) * 1989-02-10 1990-08-23 Shino-Test Corporation Method for assaying indirect agglutination
US5043101A (en) * 1983-02-08 1991-08-27 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
WO1995002185A1 (en) * 1993-07-08 1995-01-19 Fujirebio Inc. Magnetic particles with gelatin and immunoassay using the same
JPH07318561A (en) * 1994-05-24 1995-12-08 Daiichi Rajio Isotope Kenkyusho:Kk Biochemical fine particle, production thereof and immunoassay
DE4428851A1 (en) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Nanoparticles containing iron, their production and application in diagnostics and therapy
US6258607B1 (en) * 1989-10-31 2001-07-10 Fujirebio Inc. Indirect agglutination immunoassay and apparatus therefor
WO2005095969A1 (en) * 2004-03-30 2005-10-13 Universal Bio Research Co., Ltd. Magnetic particle with reactive dye linked thereto and method of protein separation and purification
CN108028113A (en) * 2015-06-26 2018-05-11 Mag基因技术私人有限公司 Embedding of the magnetic nanoparticle of protein function property in crosslinked protein matrix is not influenced

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5282723A (en) * 1975-12-02 1977-07-11 Pasteur Institut Production of magnetic gell for preparing immune enzyme
JPS52141697A (en) * 1976-03-12 1977-11-26 Technicon Instr Method of and apparatus for analyzing fluid and granular reagent
JPS57153658A (en) * 1981-03-18 1982-09-22 Fuji Zoki Seiyaku Artificial carrier and production thereof
JPS57160465A (en) * 1981-03-31 1982-10-02 Fuji Zoki Seiyaku Manufacture of artificial carrier

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5282723A (en) * 1975-12-02 1977-07-11 Pasteur Institut Production of magnetic gell for preparing immune enzyme
JPS52141697A (en) * 1976-03-12 1977-11-26 Technicon Instr Method of and apparatus for analyzing fluid and granular reagent
JPS57153658A (en) * 1981-03-18 1982-09-22 Fuji Zoki Seiyaku Artificial carrier and production thereof
JPS57160465A (en) * 1981-03-31 1982-10-02 Fuji Zoki Seiyaku Manufacture of artificial carrier

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043101A (en) * 1983-02-08 1991-08-27 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS61181967A (en) * 1984-11-01 1986-08-14 バイヤー、コーパレイシャン Magnetic reactive particle and manufacture thereof
JPS61289053A (en) * 1985-06-14 1986-12-19 Osaka Yuki Kagaku Kogyo Kk Production of 1,3-dichloroacetone
JPH0113699B2 (en) * 1985-06-14 1989-03-07 Oosaka Juki Kagaku Kogyo Kk
JPS6390766A (en) * 1986-10-03 1988-04-21 Tdk Corp Suspension of fine magnetic particles antigen-antibody with immobilized and method for measuring concentration of antigen or antibody by using said suspension
WO1990009590A1 (en) * 1989-02-10 1990-08-23 Shino-Test Corporation Method for assaying indirect agglutination
US6258607B1 (en) * 1989-10-31 2001-07-10 Fujirebio Inc. Indirect agglutination immunoassay and apparatus therefor
WO1995002185A1 (en) * 1993-07-08 1995-01-19 Fujirebio Inc. Magnetic particles with gelatin and immunoassay using the same
JPH07318561A (en) * 1994-05-24 1995-12-08 Daiichi Rajio Isotope Kenkyusho:Kk Biochemical fine particle, production thereof and immunoassay
DE4428851C2 (en) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Nanoparticles containing iron, their production and application in diagnostics and therapy
DE4428851A1 (en) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Nanoparticles containing iron, their production and application in diagnostics and therapy
WO2005095969A1 (en) * 2004-03-30 2005-10-13 Universal Bio Research Co., Ltd. Magnetic particle with reactive dye linked thereto and method of protein separation and purification
JP4804344B2 (en) * 2004-03-30 2011-11-02 ユニバーサル・バイオ・リサーチ株式会社 Reactive dye-coupled magnetic particles and protein separation and purification method
CN108028113A (en) * 2015-06-26 2018-05-11 Mag基因技术私人有限公司 Embedding of the magnetic nanoparticle of protein function property in crosslinked protein matrix is not influenced
EP3314616A4 (en) * 2015-06-26 2019-03-06 Maggenome Technologies PVT. Ltd. Entrapment of magnetic nanoparticles in a cross-linked protein matrix without affecting the functional properties of the protein
CN108028113B (en) * 2015-06-26 2020-08-25 Mag基因技术私人有限公司 Embedding of magnetic nanoparticles in a cross-linked protein matrix without affecting the functional properties of the protein

Also Published As

Publication number Publication date
JPH0317103B2 (en) 1991-03-07

Similar Documents

Publication Publication Date Title
US4416813A (en) Artificial carrier for immobilization of biological proteins
DE69909090T2 (en) NUCLEAR GENERATION AND GROWTH OF METAL OXIDE NANOPARTICLES AND USE
JPS59195161A (en) Magnetic particle and its production
US4582622A (en) Magnetic particulate for immobilization of biological protein and process of producing the same
US4331654A (en) Magnetically-localizable, biodegradable lipid microspheres
US4798786A (en) Living cells encapsulated in crosslinked protein
JP2564386B2 (en) Method for preparing powder of water-insoluble polymer
JPH09509612A (en) Gas-containing microcapsules useful as contrast agents for diagnostic imaging
RU2659949C1 (en) Method for preparing a preparation based on magnetic nanoparticles (mnch) of iron oxide for mrt-diagnosis of neoplasms
JPS6310668A (en) Dry material capable of being converted to aqueous gel containing dispersible polymer particles by hydration
CA2263765C (en) Methods for the production of protein particles useful for delivery of pharmacological agents
JPS61180713A (en) Manufacture of liposome and use
EP0129619B1 (en) Encapsulated cells, their method of preparation and use
JPS5951355A (en) Reagent for detecting antiviral antibody
EP0062968B1 (en) Support material for use in serological testing and process for the production thereof
JPH0317303B2 (en)
JPH02103470A (en) Artificial carrier and its manufacture
EP0176638B1 (en) Artificial support material for immobilisation of biological protein and process for producing the same
JPS6348021B2 (en)
Li et al. Au-poly (lactic-co-glycolic) acid complex nanoparticles as ultrasound contrast agents: Preparation, characterization and in vitro study
JPS6329223B2 (en)
JPS6332150B2 (en)
JPS58113755A (en) Production of artificial carrier
JPS6332146B2 (en)
JPS6332149B2 (en)

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term
S199 Written request for registration of transfer of right

Free format text: JAPANESE INTERMEDIATE CODE: R313199

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370